deListed Australia
 
SEARCH LISTED OR DELISTED COMPANY
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY
SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

RESAPP HEALTH LIMITED (ASX.RAP)

ASX Announcements (courtesy of ASX)

20152016201720182019202020212022

ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)
Former (or subsequent) names
CompanyFROMTO
RESAPP HEALTH LIMITED08/07/2015
NARHEX LIFE SCIENCES LIMITED08/07/2015
Shareholder links
Our website ranking of RAP: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details
ISIN: AU000000RAP5
Address: Level 12, 100 Creek Street Brisbane QLD 4000
Tel:  (07) 3724 0035 Fax: (08) 9218 8875

Date first listed: 12/01/2005

Sector: Health Care Equipment & Services
Industry Group: XHJ
Activities: Research and development of digital healthcare solutions for respiratory disease

delisted at entity's request under Listing Rule 17.11

27/09/2022

we understand Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) acquired all of the issued shares in RAP for $0.207 cash per share

27/09/2022

The company releases a notification of cessation of securities.

16/09/2022

The securities of ResApp Health Limited will be suspended from quotation at the close of trading on Thursday, 15 September 2022 under Listing Rule 17.2, following lodgement of the Supreme Court of New South Wales orders with ASIC approving the scheme of arrangement by which Pfizer Australia Holdings Pty Limited will acquire all of the issued shares in RAP.

15/09/2022

The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement.

14/06/2022

ResApp Health and Pfizer have agreed to increase the scheme consideration from A$0.115 per share in cash to: A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout Condition (Confirmed Data Consideration); or A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is not satisfied (Unconfirmed Data Consideration). Relative to ResApp's share price prior to announcement of the Initial Scheme, the Revised Scheme Consideration represents a material premium of: 130.0% based on the Confirmed Data Consideration, 62.2% based on the Unconfirmed Data Consideration. Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable and in best interests of ResApp shareholders. The ResApp Board unanimously recommends that ResApp shareholders vote in favour of the Revised Scheme.

14/06/2022

The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the update on the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Tuesday 14 June 2022.

08/06/2022

The Company requests that the voluntary suspension ends on the date the anticipated announcement in relation to the proposed acquisition by Pfizer Australia Holdings is released to the market which the Company anticipates will occur by Wednesday 8 June 2022.

06/06/2022

The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in RAP by way of a Scheme of Arrangement.

02/06/2022

The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following the release by RAP of an announcement regarding its COVID-19 study results.

22/03/2022

92% sensitivity for detecting COVID-19 with a new cough audio-based algorithm "“ exceeding the real-world measured sensitivity of rapid antigen testing. Initial market opportunities in settings where frequent testing is required "“ employee, healthcare worker and student screening, travel, sports, entertainment, and aged care. ResApp to engage with regulators on requirements for approvals and seek to partner with a global health or technology company to accelerate commercialisation.

22/03/2022

The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its COVID-19 study results.

21/03/2022

The suspension of trading in the securities of ResApp Health Limited will be lifted immediately, following the release by RAP of an announcement.

30/10/2018

The company announces positive preliminary results from its SMARTCOUGHC-2 study, a double-blind, prospective study to evaluate the efficacy of the ResAppDx smartphone application for the diagnosis of childhood acute respiratory disease.

30/10/2018

Further to the request for Voluntary Suspension on 24 October 2018, ResApp Health Limited advises that it has received the US SMARTCOUGH-C-2 study results and is currently in the process of analysing these results. The Company anticipates that it will be in a position to release a full update to the market on Tuesday 30 October 2018.

29/10/2018

The securities of ResApp Health Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis.

24/10/2018

The suspension of trading in the securities of ResApp Health Limited will be lifted immediately following receipt of an announcement.

09/08/2017

The company announced top line data from its multi-site double-blind prospective clinical study to investigate ResAppDx for the diagnosis for respiratory disease in infants and children using cough sounds.

09/08/2017

The securities of ResApp Health Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to its SMARTCOUGH-C study.

02/08/2017

The securities of ResApp Health Limited (the "Company") will be reinstated to official quotation as from 10 am EST on Tuesday, 14 July 2015, following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules. 440,523,353 ordinary shares fully paid Security Code RAP

09/07/2015

name changed from Narhex Life Sciences Limited

08/07/2015
View ASX Announcements (courtesy of ASX)

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates
Post your comments here
Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    15/03/2021Roger Aston290,000$0.070$20,300
    15/03/2021Anthony Keating225,000$0.072$16,200
    15/03/2021Chris Ntoumenopoulos500,000$0.071$35,500
    05/10/2017Brian Leedman875,885$0.074$64,512
    09/08/2017Chris Ntoumenopoulos1,000,000$0.073$72,822

    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    NAMETITLEDATE OF APPT
    Roger AstonNon Exec Chairman17/07/2015
    Anthony KeatingManaging Director, CEO02/07/2015
    Chris NtoumenopoulosNon Exec Director22/01/2015
    Robert RamsayNon Exec Director20/12/2013
    Michael SteinNon Exec Director06/04/2020
    Brian LeedmanExecutive Director22/02/2016
    Nicki FarleyCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)
    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Nathan BuzzaNon Exec Director29/12/201731/03/2020
    Adam SierakowskiNon Exec Director, Non Exec Director16/05/201322/03/2016
    Cyril D'SilvaExecutive Chairman16/05/201322/01/2015
    Peter ChristieChairman13/01/201120/12/2013
    David MandelDirector17/05/201020/12/2013
    Simon LillDirector13/01/201120/12/2013
    Ian ReynoldsDirector22/02/201330/04/2013
    Peter NashDirector07/10/200422/06/2012

    Date of first appointment, title may have changed.